Lineage Cell Therapeutics, Inc.
LCTX
$1.23
$0.010.82%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -296.19% | -241.41% | -236.42% | -69.14% | 31.49% |
| Total Depreciation and Amortization | 20.90% | 14.78% | 4.90% | -6.14% | -14.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3,018.05% | 1,207.16% | 1,358.82% | 451.74% | -71.09% |
| Change in Net Operating Assets | 26.47% | 53.11% | -3.35% | -174.73% | -50.18% |
| Cash from Operations | 0.38% | 18.07% | 10.45% | -2.47% | 3.95% |
| Capital Expenditure | 23.08% | 7.61% | -67.70% | -84.91% | -19.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6,794.94% | -642.11% | -1.77% | 168.58% | -99.18% |
| Cash from Investing | -4,719.07% | -483.06% | -5.98% | 177.35% | -101.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.27% | -9.26% | -9.43% | -5.77% | -1.85% |
| Issuance of Common Stock | 2.73% | -23.07% | 106.53% | 81.26% | 31.98% |
| Repurchase of Common Stock | -606.67% | -252.17% | 63.96% | 63.96% | 93.24% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16.46% | -300.00% | -529.65% | -458.05% | -- |
| Cash from Financing | 2.18% | -24.84% | 100.60% | 77.40% | 31.49% |
| Foreign Exchange rate Adjustments | 573.47% | 516.84% | 48.77% | 231.02% | 55.45% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -381.18% | -148.54% | 443.02% | 394.65% | -84.98% |